Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial

被引：0
|
作者：
Pozo-Rosich, P. [1 ]
Nagy, K. [2 ]
Tassorelli, C. [3 ,4 ]
Lanteri-Minet, M. [5 ]
Sacco, S. [6 ]
Nezadal, T. [7 ]
Finnegan, M. [8 ]
Guo, H. [8 ]
Gandhi, P. [8 ]
Trugman, J. [8 ]
机构：
[1] Vall DHebron Univ Hosp, Barcelona, Spain
[2] AbbVie, Budapest, Hungary
[3] C Mondino Fdn, Headache Sci & Neurorehabil Ctr, Pavia, Italy
[4] CHU Nice, Pain Dept, Nice, France
[5] CHU Nice, FHU InovPain, Nice, France
[6] Cote Azur Univ, Nice, France
[7] Charles Univ Prague, Mil Univ Hosp, Sch Med 1, Dept Neurol, Prague, Czech Republic
[8] AbbVie, Madison, NJ USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-137
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [31] Daily atogepant provides a rapid onset and sustained benefit in the preventive treatment of migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 119 - 119
  • [32] Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
    Goadsby, P.
    Pozo-Rosich, P.
    Ashina, M.
    Reuter, U.
    Moisset, X.
    Trugman, J.
    Ha, H.
    Schwefel, B.
    Nagy, K.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [33] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [34] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 160
  • [35] Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
    Tassorelli, Cristina
    Nagy, Krisztian
    Pozo-Rosich, Patricia
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Guo, Hua
    Ferreira, Rosa De Abreu
    Forero, Giovanna
    Trugman, Joel M.
    LANCET NEUROLOGY, 2024, 23 (04): : 382 - 392
  • [36] Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
    Ailani, J.
    Gandhi, P.
    Lalla, A.
    Singh, R. B. Halker
    McAllister, P.
    Smith, J. H.
    Dabruzzo, B.
    Chalermpalanupap, N.
    Nahas, S. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [37] Daily atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 118 - 118
  • [38] Efficacy of erenumab in chronic migraine patients with medication overuse and prior preventive treatment failure
    Dodick, D.
    Tepper, S.
    Diener, H. -C.
    Tassorelli, C.
    Lucas, S.
    Evers, S.
    Zhang, F.
    Chou, D.
    Tenenbaum, N.
    Klatt, J.
    Mikol, D.
    Lima, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 811 - 811
  • [39] Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure
    Dodick, David
    Tepper, Stewart J.
    Diener, Hans Christoph
    Tassorelli, Cristina
    Lucas, Sylvia
    Evers, Stefan
    Zhang, Feng
    Chou, Denise
    Tenenbaum, Nadia
    Klatt, Jan
    Mikol, Daniel
    Lima, Gabriel Paiva da Silva
    NEUROLOGY, 2019, 92 (15)
  • [40] Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
    Schwedt, Todd J.
    Lipton, Richard B.
    Ailani, Jessica
    Silberstein, Stephen D.
    Tassorelli, Cristina
    Guo, Hua
    Lu, Kaifeng
    Dabruzzo, Brett
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    CEPHALALGIA, 2022, 42 (01) : 3 - 11
12345